Document:

Exhibit 4.7

 

Form of Subordinated Note

 

(FACE OF SECURITY)

 

[Each Global Security shall bear substantially the following legend:

 

UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES
IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY
OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE
OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

 

[If the Security has original issue discount for U.S. federal income
tax purposes, insert tax legend:

 

[FOR PURPOSES OF SECTIONS 1272, 1273 AND 1275 OF THE INTERNAL REVENUE
CODE OF 1986, AS AMENDED, AND THE RULES AND REGULATIONS THEREUNDER, THIS NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT; PLEASE CONTACT
[NAME OF CFO OR TAX DIRECTOR], [TITLE], [ISSUER], [ISSUER ADDRESS], TELEPHONE: [###], TO OBTAIN INFORMATION REGARDING THE ISSUE PRICE,
THE ISSUE DATE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT AND THE YIELD TO MATURITY.]

 

     

     

    

 

XILIO THERAPEUTICS, INC.

[ Title of Security ]

 

	No. [   ]	CUSIP No.:  [   ]
	 	[Common Code][ISIN]:   [    ]
	 	[$   ]

 

Xilio Therapeutics, Inc., a Delaware corporation
(the “Issuer”, which term includes any successor corporation), for value received promises to pay to [If the Security is
a Global Security -- CEDE & CO.][If the Security is not a Global Security -- __________] or registered assigns, the
principal sum of __________ on __________,____ (the “Maturity Date”) [If the Security is to bear interest prior to maturity,
insert--, and to pay interest thereon from _____________ or from the most recent interest payment date to which interest has been
paid or duly provided for, [semiannually in arrears on ______ and ______ in each year], commencing _________, ____ (each, an “Interest
Payment Date”) at the rate of [___% per annum], until the principal hereof is paid or made available for payment [If applicable
insert--, and (to the extent that the payment of such interest shall be legally enforceable) at the rate of ___% per annum on any
overdue principal and on any overdue installment of interest]. The interest so payable, and punctually paid or duly provided for, on any
Interest Payment Date will, as provided in the Indenture (as defined below), be paid to the Holder in whose name this Security (or one
or more predecessor Securities) is registered at the close of business on the record date for such interest, which shall be the _______
or ________ (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date (each, an “Interest Record
Date”). Interest will be computed on the basis of [a 360-day year of twelve 30-day months].]

 

[If the Security is not to bear interest prior
to maturity, insert--The principal of this Security shall not bear interest except in the case of a default in payment of principal
upon acceleration, upon redemption or at maturity and, in each such case, the overdue principal of this Security shall bear interest at
the rate of ___% per annum (to the extent that the payment of such interest shall be legally enforceable), which shall accrue from the
date of such default in payment to the date payment of such principal has been made or duly provided for. Interest on any overdue principal
shall be payable on demand.]

 

Reference is made to the further provisions set
forth on the reverse of this Security contained herein, which will for all purposes have the same effect as if set forth at this place.

 

     

     

    

 

IN WITNESS WHEREOF, the Issuer has caused this
Security to be signed manually or by facsimile by its duly authorized officer under its corporate seal.

 

	 	XILIO THERAPEUTICS, INC.
	 	 	 
	 	 	 
		By:	
	 	 	Name:	                     
	 	 	Title:	 

 

Attest:

 

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

This is one of the Securities of the series designated
herein and referred to in the within-mentioned Indenture.

 

Dated:  [   ]

 

	 	____________, as Trustee
	 	 	 
	 	 	 
		By:	
	 	 	Title:	 

 

     

     

    

 

(REVERSE OF SECURITY)

 

XILIO THERAPEUTICS, INC.

 

[ Title of Security ]

 

		1.	Indenture

 

This Security is one of a duly authorized issue
of debentures, notes or other evidence of indebtedness (hereinafter called the “Securities”) of the Issuer of the series hereinafter
specified, which series is initially limited in aggregate principal amount to [$]____________, all of such Securities issued and
to be issued under an Indenture dated as of ________, _____ (the “Indenture”) between the Issuer and __________________________
as trustee (the “Trustee”). Capitalized terms herein are used as defined in the Indenture unless otherwise indicated. The
terms of the Securities include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture
Act of 1939, as in effect on the date of the Indenture. The Securities are subject to all such terms, and Holders are referred to the
Indenture and the Trust Indenture Act for a statement of all such terms. To the extent permitted by applicable law, in the event of any
inconsistency between the terms of this Security and the terms of the Indenture, the terms of the Indenture shall control.

 

This Security is one of a series of Securities
designated pursuant to the Indenture [and a [Supplemental Indenture] dated _____, _____, issued pursuant to Section 2.01 and
Section 2.03 thereof (the “Supplemental Indenture”)] as ________________. The Securities are general unsecured obligations
of the Issuer. The Issuer may, subject to the provisions of the Indenture and applicable law, issue additional Securities of any series
under the Indenture.

 

		2.	Method of Payment.

 

The Issuer shall pay interest on the Securities
(except defaulted interest) to the persons who are the registered Holders at the close of business on the Interest Record Date immediately
preceding the Interest Payment Date notwithstanding any transfer or exchange of such Security subsequent to such Interest Record Date
and prior to such Interest Payment Date. Holders must surrender Securities to the Trustee to collect principal payments. The Issuer shall
pay Principal and interest in money of [the United States] that at the time of payment is legal tender for payment of public and
private debts. [However, the payments of interest, and any portion of the Principal (other than interest payable at maturity or on any
redemption or repayment date or the final payment of Principal) shall be made by the Paying Agent, upon receipt from the Issuer of immediately
available funds by __________ [a./p.m.], New York City time (or such other time as may be agreed to between the Issuer and the
Paying Agent or the Issuer), directly to a Holder (by Federal funds wire transfer or otherwise) if the Holder has delivered written instructions
to the Trustee 15 days prior to such payment date requesting that such payment will be so made and designating the bank account to which
such payments shall be so made and in the case of payments of principal surrenders the same to the Trustee in exchange for a Security
or Securities aggregating the same principal amount as the unredeemed principal amount of the Securities surrendered.]

 

     

     

    

 

		3.	Redemption.

 

[The Securities of this series may be redeemed
at any time [on or after ______, ______], as a whole or in part, at the option of the Issuer, upon mailing notice of such
redemption not less than 10 and not more than 60 days to the Holders of such Securities, at a redemption price equal to ___________.]

 

		4.	Paying Agent and Security Registrar

 

Initially, [the Trustee] will act as Paying Agent
and Security Registrar.  The Issuer may change any Paying Agent or Security Registrar without notice to the Holders.

 

		5.	Denominations; Transfer; Exchange.

 

The Securities are in registered form, without
coupons, in denominations of [$2,000] and multiples of [$1,000]. A Holder shall register the transfer of or exchange Securities
in accordance with the Indenture. The Issuer may require a Holder, among other things, to furnish appropriate endorsements and transfer
documents and to pay certain transfer taxes or similar governmental charges payable in connection therewith as permitted by the Indenture.
[The Issuer need not register the transfer of or exchange (a) any Securities for a period of fifteen (15) days preceding the first
notice that such Securities are to be redeemed, or (b) any Securities selected, called or being called for redemption in whole or
in part, except, in the case of any Security to be redeemed in part, the portion thereof not to be so redeemed.]

 

		6.	Persons Deemed Owners.

 

The registered Holder of a Security shall be treated
as the owner of it for all purposes.

 

		7.	Unclaimed Funds.

 

If funds for the payment of principal or interest
remain unclaimed for two years, the Trustee and the Paying Agent will repay the funds to the Issuer. After that, all liability of the
Trustee and such Paying Agent with respect to such funds shall cease.

 

		8.	Defeasance.

 

The Indenture [as amended by the Supplemental
Indenture] contains provisions for defeasance at any time of (a) the entire indebtedness of the Issuer on this Security and (b) certain
restrictive covenants and the related Events of Default, upon compliance by the Issuer with certain conditions set forth therein, which
provisions [apply] to this Security.

 

		9.	Amendment; Supplement; Waiver.

 

Subject to certain exceptions, the Securities of
this series, [the Supplemental Indenture] and the provisions of the Indenture relating to the Securities of this series may be amended
or supplemented with the written consent of the Holders of at least a majority in aggregate principal amount of the Securities of this
series then outstanding, and any existing Default or Event of Default, other than the non-payment of the principal amount of or interest
on the Securities of this series, or compliance with certain provisions may be waived with the consent of the Holders of a majority in
aggregate principal amount of all the Securities of this series, then outstanding. Without notice to or consent of any Holder, the parties
thereto may amend or supplement the Indenture and the Securities to, among other things, cure any ambiguity, defect or inconsistency,
provide for uncertificated Securities in addition to or in place of certificated Securities, or make any other change that does not adversely
affect the rights of any Holder of a Security.

 

     

     

    

 

		10.	Defaults and Remedies.

 

If an Event of Default (other than certain bankruptcy
Events of Default with respect to the Issuer) occurs and is continuing, the Trustee or the Holders of at least 25% in aggregate principal
amount of Securities of this series then outstanding (voting as a separate class) by notice in writing to the Issuer (and also to the
Trustee if such notice is given by the Holders) may declare [the entire principal] of the Securities of this series and the interest
accrued thereon, if any, to be due and payable immediately in the manner and with the effect provided in the Indenture. If a bankruptcy
Event of Default with respect to the Issuer occurs and is continuing, then [the entire principal] of the Securities then outstanding
and interest accrued thereon, if any, shall become automatically due and payable immediately in the manner and with the effect provided
in the Indenture.  Holders of Securities may not enforce the Indenture or the Securities except as provided in the Indenture.
The Trustee is not obligated to enforce the Indenture or the Securities unless it has received indemnity satisfactory to it. The Indenture
permits, subject to certain limitations therein provided, Holders of a majority in aggregate principal amount of the Securities then outstanding
to direct the Trustee in its exercise of any trust or power. The Trustee may withhold from Holders of Securities notice of certain continuing
Defaults or Events of Default if it determines that withholding notice is in their interest.

 

		11.	Subordination.

 

Reference is made to the Indenture, including,
without limitation, provisions subordinating the payment of principal of and premium, if any, and interest on the Securities to the prior
payment in full of all Senior Indebtedness as defined in the Indenture.  Such further provisions shall for all purposes have
the same effect as though fully set forth at this place.

 

		12.	Trustee Dealings with Issuer.

 

The Trustee under the Indenture, in its individual
or any other capacity, may become the owner or pledgee of Securities and may otherwise deal with the Issuer as if it were not the Trustee.

 

		13.	No Recourse Against Others.

 

No stockholder, director, officer, employee or
incorporator, past, present or future as such, of the Issuer or any predecessor or successor corporation thereof shall have any liability
for any obligation under the Securities or the Indenture or for any claim based on, in respect of or by reason of, such obligations or
their creation. Each Holder of a Security by accepting a Security waives and releases all such liability. The waiver and release are part
of the consideration for the issuance of the Securities.

 

     

     

    

 

		14.	Authentication.

 

This Security shall not be valid until the Trustee
manually signs the certificate of authentication on this Security.

 

		15.	Abbreviations and Defined Terms.

 

Customary abbreviations may be used in the name
of a Holder of a Security or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint
tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act).

 

		16.	CUSIP Numbers.

 

Pursuant to a recommendation promulgated by the
Committee on Uniform Security Identification Procedures, the Issuer has caused CUSIP numbers to be printed on the Securities as a convenience
to the Holders of the Securities. No representation is made as to the accuracy of such numbers as printed on the Securities and reliance
may be placed only on the other identification numbers printed hereon.

 

		17.	Governing Law.

 

The laws of the State of New York shall govern
the Indenture and this Security thereof, and for all purposes this Security shall be governed by and construed in accordance with the
laws of such State without regard to any principle of conflict of laws that would require or permit the application of the laws of any
other jurisdiction, except as may otherwise be required by mandatory provisions of law.

 

     

     

    

 

ASSIGNMENT FORM

 

I or we assign and transfer this Security to

 

	 
	(Print or type name, address and zip code of assignee or transferee)
	 
	 
	(Insert Social Security or other identifying number of assignee or transferee)

 

and irrevocably appoint ______________________________________________
agent to transfer this Security on the books of the Issuer.  The agent may substitute another to act for him.

 

	Dated:	 	 	Signed:	 
	 	 	 	 	(Signed exactly as name appears on the other side of this Security)

 

	Signature

Guarantee:

	 	 

	 	Participant in a recognized Signature
Guarantee Medallion Program (or other signature guarantor program reasonably
acceptable to the Trustee)Exhibit 10.1

 

AMENDMENT
NUMBER 1

TO

VOTING
AGREEMENT

 

THIS
AMENDMENT NUMBER 1 TO VOTING AGREEMENT (this “Amendment”)
is made effective as of November 7, 2022, and amends that certain Voting Agreement, effective as of June 16, 2022 (the “Voting
Agreement”), by and among Reviv3 Procare Company, a Delaware corporation (the “Company”), Intrepid
Global Advisors, Inc., a Delaware corporation (“Intrepid”), and Axil & Associated Brands Corp., a Delaware
corporation (“Axil”).

 

RECITALS

 

WHEREAS,
the parties to the Voting Agreement hereby desire to amend the Voting Agreement to revise the securities exempted from the term “New
Securities”, on the terms and subject to the conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the foregoing recital and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties to this Amendment agree as follows:

 

		1.	Section
                                            1 of the Voting Agreement is amended and restated in its entirety to read as follows:

 

“1.
Issuance of New Securities. During the Lock Up Period, as defined in the Purchase Agreement, no New Securities may be issued
by the Company without the approval of both Intrepid and Axil, so long as Axil holds of a majority of the outstanding Preferred Shares
(as defined in the Purchase Agreement). “New Securities” means any capital stock (including common and preferred)
of the Company whether now authorized or not, and rights, options or warrants to purchase capital stock, and securities of any type whatsoever
that are, or may become, convertible into capital stock; provided, that the term “New Securities” does not
include (A) securities issuable upon conversion of or with respect to the Preferred Shares; (B) securities issued upon exercise of options
or warrants; (C) securities issued pursuant to the acquisition of another entity by the Company (directly or through a subsidiary) by
merger, purchase of substantially all the assets or other reorganization whereby the Company directly or indirectly owns more than fifty
percent (50%) of the voting power of such entity; (D) any borrowings, directly or indirectly, from financial institutions, equipment
leasing companies or other persons or entities by the Company or a subsidiary, whether or not presently authorized, including any type
of loan or payment evidenced by any type of debt instrument; (E) shares of common stock (including options to purchase such shares) issued
to employees, consultants or directors of the Company or a subsidiary pursuant to any existing or future stock option plan or stock purchase
or stock bonus agreement or arrangement approved by the Board of Directors of the Company or any subsidiary; (F) securities issued in
connection with obtaining lease financing; (G) securities issued pursuant to any stock dividend, stock split, combination or other reclassification
by the Company of any of its capital stock; (H) any right, option or warrant to acquire any security convertible into the securities
excluded from the definition of New Securities; (I) securities issued in connection with any private placements exempt from registration
under federal or state securities laws; or (J) securities issued in connection with any securities offerings by the Company in an amount
up to $50.0 million per offering.”

 

    1

     

    

		2.	Except
                                            as specifically amended hereby, all of the terms of the Voting Agreement shall remain in
                                            full force and effect and are hereby ratified and confirmed. Without limiting the generality
                                            of the foregoing, the amendment contained herein will not be construed as an amendment to
                                            or waiver of any other provision of the Voting Agreement or as a waiver of or consent to
                                            any further or future action on the part of any party that would require the waiver or consent
                                            of another party.

 

		3.	Capitalized
                                            terms used and not defined in this Amendment have the respective meanings assigned to them
                                            in the Voting Agreement.

 

		4.	This
                                            Amendment is governed by and construed in accordance with the laws of the State of Delaware,
                                            without regard to the conflict of laws provisions of such State.

 

		5.	This
                                            Amendment shall inure to the benefit of and be binding upon each of the parties and each
                                            of their respective successors and assigns.

 

		6.	This
                                            Amendment may be executed and delivered in multiple counterparts, each of which shall be
                                            deemed an original, and all of which together shall constitute one and the same instrument.
                                            Delivery of an executed counterpart of this Amendment electronically or by facsimile shall
                                            be effective as delivery of an original executed counterpart of this Amendment.

 

		7.	This
                                            Amendment constitutes the sole and entire agreement between the parties with respect to the
                                            subject matter contained herein, and supersedes all prior and contemporaneous understandings,
                                            agreements, representations, and warranties, both written and oral, with respect to such
                                            subject matter.

 

[Signature
Page Follows]

 

    2

     

    

IN
WITNESS WHEREOF, the Company, Intrepid and Axil have duly executed this Amendment as of the date first written above.

 

	 	The
    Company:
	 	Reviv3
    Procare Company
	 	 	 
	 	By:	/s/
    Jeff Toghraie
	 	 	Name: 
    Jeff Toghraie
	 	 	Title:
    Chief Executive Officer
	 	 	 
	 	Intrepid:
	 	Intrepid
    Global Advisors, Inc.
	 	 	 
	 	By:	/s/
    Jeff Toghraie
	 	 	Name: 
    Jeff Toghraie
	 	 	Title:
    Managing Director
	 	 	 
	 	Axil:
	 	Axil
    & Associated Brands Corp.
	 	 	 
	 	By:	/s/
    Weston Harris
	 	 	Name: 
    Weston Harris
	 	 	Title:
    Chief Executive Officer

 

[Signature Page to Amendment No. 1 to Voting Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]